Karuna Therapeutics

News

BMS completes $14bn takeover of Karuna

Bristol-Myers Squibb has got its $14 billion acquisition of Karuna Therapeutics over the line, having had to withdraw and refile antitrust paperwork and contend with a sha

News

Steve Davis, president and chief executive of Acadia Pharma

Acadia pulls trials of pimavanserin after schizophrenia fail

Acadia Pharma’s plan to develop pimavanserin as a treatment for additional indications is in disarray after the drug failed a phase 3 trial in schizophrenia.

News

BMS wagers $14bn on Karuna’s schizophrenia drug

Bristol-Myers Squibb has decided to gamble on the FDA approving Karuna Therapeutics’ schizophrenia drug candidate KarXT next year, agreeing to buy the company for approxim

News

FDA kicks off review of Karuna’s schizophrenia drug KarXT

Karuna Therapeutics said this morning that the FDA has formally started its review of KarXT, aiming to become the first drug to reach the market for schizophrenia with a n

News

Sumitomo's novel schizophrenia drug flunks phase 3 test

After decades of stagnation in the drug treatment of schizophrenia, a handful of new therapies have raised hopes of improvement – but one of them has just failed a pair of

News